First-in-class small molecule modulators of RNA
Arrakis is building a proprietary platform to enable the rational, structure-based design of orally acting small molecules that bind RNA, and so directly modulate RNA function.
CEO Michael Gilman
Advent founded Arrakis in 2014.
Advent Life Sciences Announces Growth of Investment Team with Three Senior Appointments
Press Release. 26 May 2022, London, UK: Advent Life Sciences, a leading transatlantic venture and growth investor focused on building innovative life science companies in the UK, Europe, and…Read More
Advent Life Sciences’ founded Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets
Press Release. This investment will fund Amphista Therapeutics’ growing pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and extend its proprietary platform. London, UK,…Read More
Advent Life Sciences Becomes Latest Partner of One Nucleus
Press Release. Cambridge and London UK: 12th March 2021 Advent Life Sciences, one of the sector’s leading Trans-Atlantic venture investors has become the latest Partner to join One Nucleus.…Read More